High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment

The aim of this study was to analyze the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) L265P in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). We assessed the MYD88 L265P m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Sisi, Luo, Huaichao, Pan, Meiling, Palomino, Luis Angel, Song, Xiaoyu, Wu, Ping, Huang, Jian-Ming, Zhang, Zhihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780752/
https://www.ncbi.nlm.nih.gov/pubmed/29403563
http://dx.doi.org/10.3892/ol.2017.7472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780752/
https://www.ncbi.nlm.nih.gov/pubmed/29403563
http://dx.doi.org/10.3892/ol.2017.7472

Ejemplares similares